Navigation Links
Phosphagenics Initiates U.S. Clinical Trials for Its Topical Retinoic Acid
Date:2/19/2008

MELBOURNE, Australia, Feb. 19 /PRNewswire-FirstCall/ -- Phosphagenics Limited ("Phosphagenics") (ASX: POH; AIM: PSG; OTCQX: PPGNY) today announced the initiation of a human clinical trial for its lead dermatological product, retinoic acid, a form of vitamin A. This trial represents the Company's first clinical trial to take place in the U.S. and denotes the commencement of the Company's planned expansion into targeted, non-systemic delivery of drugs.

This trial follows a number of pre-clinical studies that demonstrated both an increase in dermal absorption of retinoic acid when formulated with Phosphagenics' proprietary drug delivery platform (TPM), and a significant reduction in irritation scores. The clinical trial is a double blinded study that will involve 90 subjects and is being conducted at Broomall, PA-based cyberDERM Inc., a contract research organization focused on developing and refining innovative bio-instrumental and computerized methods for non-invasive analysis of skin structure, its functions and effects of topical treatments. This trial is expected to be completed by the end of the second quarter, 2008.

According to the American Journal of Dermatology, retinoic acid is prescribed most often as the topical treatment of choice for acne. However, it is poorly soluble, is associated with irritation and dryness of the skin and, in some cases, can cause liver damage when substantial amounts enter the systemic circulation. Irritation, though, is the most common adverse effect and is observed in approximately 90% of users. Additionally, according to The American Dermatological Association Inc., half of the patients who end their retinoic acid treatment cycle prematurely do so because of irritation. Consequently, practitioners are often reluctant to prescribe retinoic acid in large quantities and, typically, marketed formulations contain between only 0.025% and 0.1% of the active, which often serves to dilute the effectiveness of retinoi
'/>"/>

SOURCE Phosphagenics Limited
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Update on Progression of Phosphagenics and Nestle Nutritions Phospha E(R) Trial
2. Nestle Nutrition and Phosphagenics to Commence Phospha E(R) Phase 2 Clinical Trial
3. Phosphagenics to Conduct a Phase 1 Transdermal Oxycodone Clinical Trial
4. Phosphagenics to Commence Phase 2 TPM/Insulin Clinical Trial
5. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
6. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
7. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
8. Nuvelo Initiates Phase 1 Clinical Trial of Thrombin Inhibitor, NU172
9. Northwestern Memorial Transplant Program Initiates New Study
10. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
11. SGX Initiates Phase I Trials for SGX523
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...ence Call Scheduled for Tuesday, December 9 at 11:...- , , SOUTH SAN FRANCISCO, Calif., Dec. 1 ...s, Inc. (Nasdaq: SNSS ), a biopharmaceutical com...ion of new oncology therapeutics, today announced ...eloid leukemia (AML) will be presented during the ...
(Date:11/30/2008)... CHICAGO, Dec. 1 Olde...ebral blood flow and a greater number of small blo...sented today at the annual meeting of the Radiolog...The study, conducted at the University of North C...mpare brain scans of older adults who exercise to ...
(Date:11/28/2008)...LIS, Nov. 28 Eli Lilly a...emental New Drug Application (sNDA) from,the U.S....) (duloxetine HCl),for the management of chronic ...the first half of 2009, adding data from a recentl...tis pain of the knee. , The decision does n...
(Date:11/26/2008)... information density, automation and intelligent c...ltrasound to an all new level , , CHICAGO, ... Healthcare ( www.siemens.com/healthcare ) highl... Scanner (ABVS)(1), the world,s first multi-use, ...94th Scientific Assembly and Annual Meeting of the...
Breaking Medicine Technology:Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 2Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia To Be Presented at ASH 3Exercise Helps Prevent Age-Related Brain Changes in Older Adults 2Exercise Helps Prevent Age-Related Brain Changes in Older Adults 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Siemens Introduces New Standard of Care for Breast Ultrasound 2Siemens Introduces New Standard of Care for Breast Ultrasound 3Siemens Introduces New Standard of Care for Breast Ultrasound 4Siemens Introduces New Standard of Care for Breast Ultrasound 5Sexually transmitted disease urinary tract infections may be bad combination for birth defect 22432 1Sexually transmitted disease urinary tract infections may be bad combination for birth defect 22432 2Sexually transmitted disease urinary tract infections may be bad combination for birth defect 22432 3Sickle Cell Drug Underused by Physicians 22429 1Sickle Cell Drug Underused by Physicians 22429 2Global Healer and YouTube Guru Dattatreya Siva Baba Starts Worldwide City Tour on July 2 in New York City 3A Grace Light Is Coming to Solve Mankind 22425 1Global Healer and YouTube Guru Dattatreya Siva Baba Starts Worldwide City Tour on July 2 in New York City 3A Grace Light Is Coming to Solve Mankind 22425 2Warning for teens 3A Teeth and jewelry dont mix 22422 1Warning for teens 3A Teeth and jewelry dont mix 22422 2
...7 - In a late-breaker,presentation at the 42nd Ann...udy of the Liver (EASL), researchers today present...VE 1 clinical trial,which is the first trial to e...ional hepatitis C protease inhibitor telaprevir (T...on (peg-IFN) and,ribavirin (RBV) in treatment-naiv...
... Underway at Nine,Centers, SAN DIEGO, Calif., Apri...armaceutical company, today presented long term,fo...-120, a gene,therapy product in development for th...a 36 percent (p<0.001) reduction in,Parkinson,s sy...red,by the Unified Parkinson,s Disease Rating Scal...
Other Medicine Technology:Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 2Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 3Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 4Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 5Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 6Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 7Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C 8Ceregene Presents Long Term Follow-Up Data From Phase 1 Trial of,CERE-120 Demonstrating Improved Motor Function in Parkinson's,Patients 2Ceregene Presents Long Term Follow-Up Data From Phase 1 Trial of,CERE-120 Demonstrating Improved Motor Function in Parkinson's,Patients 3Ceregene Presents Long Term Follow-Up Data From Phase 1 Trial of,CERE-120 Demonstrating Improved Motor Function in Parkinson's,Patients 4
(Date:12/1/2008)...ENTO, Calif., Dec. 1 In the face o...to face the nation, the Sutter Health Board of,Di...-billion dollars to fully,fund the Sutter Health ...,often heavily invested in stocks and bonds, have...s worsening economy. Although conservatively,inve...
(Date:12/1/2008)...STER, Minn. - Disturbing evidence of higher mortal...th mitral valve prolapse and severe leakage may be...tion,s severity in women, according to findings of...Annals of Internal Medicine . , Mitral valve pro...ldwide and often requires cardiac surgery, prefera...
(Date:12/1/2008)...-Walker Chooses Two Tampa Beneficiaries for Par an... TAMPA, Fla., Dec. 1 Th...harity of Tampa Bay, Inc. and the Judeo Christian ... the 2009 Par and Poker Celebrity Challenge for Ch... , , "It is only appropriate that events li...
(Date:12/1/2008)...l, nicotine use, personality illnesses common, stu...News) -- Psychiatric disorders are common among yo...tment, a new report shows. , To reach this find... 5,000 respondents, aged 19 to 25, who took part i... Related Conditions. , The study found that 45....
Breaking Medicine News(10 mins):Health News:Sutter Health Invests Hundreds of Millions in Employee Pension 2Health News:Women with mitral valve prolapse are treated less aggressively than men and may be at high risk 2Health News:Celebrity Event Gives Local Non-Profits a Reason to be Thankful 2Health News:Few Young Adults Seek Treatment for Psych Disorders 2
... is reconsidering and mulling over the veracity of.../ a link between heavy cell phone use and an incre...n an academic exercise conducted by researchers at...rking Life who conducted a comparative study betwe...
...Australia to stop the misuse and stocking up of th... automatically// via text messages alerting them t...se drugs at pharmacies. In this new online program...taining pseudoephedrine, they will have to show ph...
...to determine the chemical composition of materials...iruses// especially in complex environmental sampl...hool of Public Health successfully separated, pur...urrogate from a clinical sample within a few hours...
...presence of the dangerous H5N1 strain of bird flu ... Following this news, there has been ample furore... Britain, but officials have been trying their bes...bout the possible spread of the disease in humans....
Other Medicine News:
...hrotek® Precision Hand Instruments were develo...eel, while still having an instrument with the str...ar of the bending or breaking. Arthrotek Hand Inst... to conform to the surgeon's hand. This new genera...
...hrotek® Precision Hand Instruments were develo...eel, while still having an instrument with the str...ar of the bending or breaking. Arthrotek Hand Inst... to conform to the surgeon's hand. This new genera...
...hrotek® Precision Hand Instruments were develo...eel, while still having an instrument with the str...ar of the bending or breaking. Arthrotek Hand Inst... to conform to the surgeon's hand. This new genera...
...hrotek® Precision Hand Instruments were develo...eel, while still having an instrument with the str...ar of the bending or breaking. Arthrotek Hand Inst... to conform to the surgeon's hand. This new genera...
Medicine Products: